ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Health Technology

Takara Bio Inc.

Business Summary

Takara Bio, Inc. is engaged in the development and marketing of genetic engineering technologies. It operates through the following business segments: Genetic Engineering Research, AgriBio, and Gene Medicine. The Genetic Engineering Research segment offers research reagents, scientific instruments, and contract research services that are essential for biotechnology research. The AgriBio segment develops a business centered in technologies for the production of health food products and mushrooms, including Hatakashimeji and Honshimeji mushrooms. The Gene Medicine segment conducts clinical development projects as it works toward commercializing cell and gene therapies centered on gene transduction method and a lymphocyte expansion culture systems. The company was founded on April 1, 2002 and is headquartered in Otsu, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue34,565M317.90M
Gross Profit20,519M188.72M
Operating income6,276M57.72M
Income before tax5,433M49.96M
Net income3,820M35.13M
EBITDA9,806M90.19M
Diluted EPS31.710.29
Dividends Per Share80.07
Total Assets76,343M707.17M
Total liabilities9,751M90.32M
Total equity66,496M615.96M
Operating cash flow6,339M58.30M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 29,729M 29,375M 32,312M 35,841M 34,565M
Gross Profit 15,789M 16,387M 18,079M 20,179M 20,519M
Operating income 2,667M 3,204M 3,556M 5,465M 6,276M
Income before tax 2,905M 2,805M 3,361M 4,823M 5,433M
Net income 1,334M 1,353M 2,335M 3,658M 3,820M
EBITDA 4,734M 5,253M 6,773M 8,840M 9,806M
Diluted EPS 11.08 11.22 19.39 30.37 31.71
Dividends Per Share 1.80 4 4.50 7 8
Total Assets 66,591M 67,143M 70,237M 72,517M 76,343M
Total liabilities 6,481M 7,154M 8,278M 8,421M 9,751M
Total equity 60,008M 59,885M 61,853M 64,010M 66,496M
Operating cash flow 3,021M 3,584M 3,935M 5,783M 6,339M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 247.56M 271.26M 291.53M 323.19M 317.90M
Gross Profit 131.48M 151.32M 163.12M 181.96M 188.72M
Operating income 22.20M 29.58M 32.08M 49.28M 57.72M
Income before tax 24.19M 25.90M 30.32M 43.49M 49.96M
Net income 11.10M 12.49M 21.06M 32.98M 35.13M
EBITDA 39.42M 48.50M 61.11M 79.71M 90.19M
Diluted EPS 0.09 0.10 0.17 0.27 0.29
Dividends Per Share 0.01 0.03 0.04 0.06 0.07
Total Assets 592.47M 602.55M 660.43M 655.16M 707.17M
Total liabilities 57.66M 64.20M 77.83M 76.08M 90.32M
Total equity 533.90M 537.42M 581.59M 578.30M 615.96M
Operating cash flow 25.15M 33.09M 35.50M 52.14M 58.30M

Valuation Measures

Mar 2020
PER70.34
ROA5.13%
ROE5.85%
Operating margin18.15%
Profit margin11.05%

Key executives

  • Executive President & Representative Director: Koichi Nakao
  • Executive Officer, Head-Finance & Business Support: Masaharu Watabe
  • Representative Director & Executive Vice President: Shuichiro Matsuzaki
  • Executive Officer & Head-Sales Planning: Masanari Kitagawa
  • Managing Director & Managing Executive Officer: Junichi Mineno

Shareholders

  • Takara Holdings Inc. (60.9%)
  • Nomura Asset Management Co., Ltd. (1.5%)
  • Shiozumi Asset Management Co. Ltd. (1.1%)
  • The Vanguard Group, Inc. (1.1%)
  • JPMorgan Asset Management (Asia Pacific) Ltd. (0.6%)
  • Daiwa Asset Management Co. Ltd. (0.5%)
  • Nikko Asset Management Co., Ltd. (0.5%)
  • Norges Bank Investment Management (0.5%)
  • BlackRock Fund Advisors (0.4%)
  • The Bank of Kyoto, Ltd. (0.4%)

Contact Details

Related Companies

  • Cellectis AB
  • DSS Takara Bio India Pvt Ltd.
  • Takara Biomedical Technology (Beijing) Co., Ltd.
  • Takara Bio USA Holdings, Inc.
  • M's Science Corp. /Anti-Cancer Drug Division/
  • Takara Bio Employee Stock Ownership Plan

Competitors

  • NantKwest, Inc.
  • Idera Pharmaceuticals, Inc.
  • Adaptimmune Therapeutics PLC Sponsored ADR
  • Oncolys BioPharma, Inc.
  • Phio Pharmaceuticals Corp.
  • uniQure N.V.
Last Updated on 20 Nov, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more